News Detail

Lantern Pharma prices registered direct offering at $2.06 per share, raises $4.4 million

PUBT · 2d ago

Listen to the news

Lantern Pharma prices registered direct offering at $2.06 per share, raises $4.4 million

Lantern Pharma priced registered direct offering of 2,135,923 common shares or pre-funded warrants at USD 2.06 each.
Concurrent private placement to issue unregistered warrants for up to 2,135,923 shares, exercise price USD 2.27, exercisable in six months, five-year term.
Gross proceeds expected at about USD 4.4 million, with up to about USD 4.85 million more if warrants are exercised for cash.
Closing expected on or about May 14, 2026, subject to customary conditions.
Net proceeds earmarked for working capital, general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260513454439) on May 13, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.